Aridis Pharmaceuticals Inc (ARDS)

OTC Markets
Currency in USD
0.010
0.000(0.00%)
Closed
ARDS Scorecard
Full Analysis
Stock generally trades with high price volatility
Fair Value
Day's Range
0.0100.010
52 wk Range
0.0010.080
Key Statistics
Edit
Prev. Close
-
Open
0.01
Day's Range
0.01-0.01
52 wk Range
0.001-0.08
Volume
-
Average Volume (3m)
258
1-Year Change
-88.1%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ARDS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Aridis Pharma Company Profile

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Compare ARDS to Peers and Sector

Metrics to compare
ARDS
Peers
Sector
Relationship
P/E Ratio
0.0x−3.9x−0.5x
PEG Ratio
0.000.020.00
Price/Book
0.0x2.4x2.6x
Price / LTM Sales
0.0x24.8x3.0x
Upside (Analyst Target)
0.0%153.2%56.3%
Fair Value Upside
Unlock−10.8%10.0%Unlock

Earnings

Latest Release
Feb 26, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Aridis Pharma (ARDS) Stock Price Today?

The Aridis Pharma stock price today is 0.01.

What Stock Exchange Does Aridis Pharma Trade On?

Aridis Pharma is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Aridis Pharma?

The stock symbol for Aridis Pharma is "ARDS."

What Is the Aridis Pharma Market Cap?

As of today, Aridis Pharma market cap is 533.21K.

What is Aridis Pharma Earnings Per Share?

The Aridis Pharma EPS is -0.035.

What Is the Next Aridis Pharma Earnings Date?

Aridis Pharma will release its next earnings report on 19 May 2025.

From a Technical Analysis Perspective, Is ARDS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.